When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Kimberly-Clark (NYSE:KMB) from Buy to Hold.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...